Abstract Spinal cord sarcoidosis is a rare manifestation of sarcoidosis. Magnetic resonance imaging (MRI) of spinal cord sarcoidosis sometimes resembles that of the non-inflammatory spinal cord lesion.
Introduction
Neurosarcoidosis has traditionally been considered a rare complication of systemic sarcoidosis, but recent progress in diagnostic imaging has found that subclinical neurosarcoidosis may not be as uncommon in patients with sarcoidosis as previously thought [1] . Nevertheless, spinal sarcoidosis is a particularly rare manifestation of neurosarcoidosis [2] .
A diagnosis of spinal cord sarcoidosis is difficult due to the invasive nature of central nervous system biopsies and primarily depends on first certifying systemic sarcoidosis. In addition, the appearance of spinal cord sarcoidosis in cervical magnetic resonance imaging (MRI) sometimes resembles that of spondylotic myelopathy or other noninflammatory spinal cord lesions [3] . In cases of cervical spondylosis associated with spinal cord sarcoidosis, extensive cervical laminoplasty has been shown to be ineffective [3] . Furthermore, treatment of spinal cord sarcoidosis with, for example, corticosteroids is quite different in these other diseases. To choose an effective therapeutic strategy, it is important to differentiate spinal cord sarcoidosis lesions from other non-inflammatory spinal cord lesions.
Recently, 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) was reported to be useful in detecting neurosarcoidosis and spinal cord sarcoidosis [4, 5] . However, no study thus far has compared neurosarcoidosis and other non-inflammatory, non-neoplastic lesions from the standpoint of intramedullary spinal cord lesions with canal stenosis. FDG-PET has the potential to improve the accuracy of diagnosing spinal cord sarcoidosis and expand the diagnostic criteria of neurosarcoidosis. The purpose of this study was to evaluate the usefulness of FDG-PET in differentiating between spinal cord sarcoidosis and other non-inflammatory, non-neoplastic spinal cord lesions.
Methods
We retrospectively reviewed the records of patients who underwent both spinal MRI and FDG-PET scans in Hokkaido University Hospital from April 2004 to March 2010. Patients with spinal cord sarcoidosis were diagnosed with neurosarcoidosis using the criteria proposed by Zajicek et al. [6] . According to these criteria, a diagnosis of ''definite'' is defined as a clinical presentation suggestive of neurosarcoidosis and the presence of positive nervous system histology. A diagnosis of ''probable'' is defined as a clinical syndrome suggestive of neurosarcoidosis, with laboratory support for CNS inflammation and evidence for systemic sarcoidosis. A diagnosis of ''possible'' is defined as a clinical presentation suggestive of neurosarcoidosis in which the above criteria are not met.
Non-inflammatory lesions were diagnosed by radiologists based on MRI and clinical records. Exclusion of sarcoidosis was based on clinical records and without 
Result
Patient demographics and SUV data are summarized in Table 1 . There were two patients with non-inflammatory spinal cord lesions that had gadolinium enhancement in MRI. Additional characteristics of patients with spinal cord sarcoidosis are shown in Table 2 
Discussion
This comparative study demonstrated the potential usefulness of FDG-PET in distinguishing spinal cord sarcoidosis from other non-inflammatory spinal cord lesions. Previous reports have focused on cerebrospinal fluid and showed that measurement of angiotensin-converting enzyme was a reliable method to detect neurosarcoidosis [7] ; however, this method may not be sensitive enough to rule out other diagnoses. Similarly, gadolinium enhancement of MRI has been used to diagnose neurosarcoidosis, but spondylotic myelopathy sometimes shows gadolinium enhancement that resembles spinal cord sarcoidosis [8] . Furthermore, cervical spondylosis occasionally causes spinal cord edema resembling an intramedullary tumor or inflammatory lesion [9] . Another study of systemic sarcoidosis demonstrated that the uptake seen in FDG-PET is associated with hypermetabolism of lesions [10] . Uptake by spinal cord lesions in this study was consistent with the systemic lesions of sarcoidosis. Myelomalacia did not show uptake using FDG-PET, perhaps due to reduced metabolic activity caused by mechanical compression [10] . However, spondylotic edematous myelopathy and dural AVF with gadolinium enhancement in MRI did show a slightly increased SUV. Gadolinium enhancement might be caused by a breakdown of the blood-cord barrier, indicating that a slightly higher SUV cannot exclude non-inflammatory spinal cord lesions. In the present study, this qualitative difference was detected as a difference of SUV in FDG-PET scans. Since the invasiveness of spinal cord biopsies makes diagnosing spinal cord sarcoidosis difficult, FDG-PET can play an important role in the differential diagnosis. In particular, the evaluation of metabolic activity by FDG-PET provides information about lesions that is crucial in the diagnosis of solitary spinal cord sarcoidosis.
There are several limitations in this study. First, we did not compare spinal cord sarcoidosis with other forms of myelitis including multiple sclerosis, neuromyelitis optica, or infectious myelitis. Therefore, a difference of SUV in FDG-PET in those diseases could not be examined. Second, this study consisted of a small number of subjects collected retrospectively, which did not allow us to evaluate the diversity of SUV in spinal cord sarcoidosis. Taken together, these limitations indicate that a larger prospective study that includes inflammatory disorders such as multiple sclerosis and that evaluates the difference in SUV before and after treatment for spinal cord sarcoidosis is necessary.
In conclusion, the use of FDG-PET is a novel approach for detecting spinal cord sarcoidosis and can distinguish it from non-inflammatory, non-neoplastic spinal cord lesions in clinical practice. Further investigations to evaluate the reliability of SUV in FDG-PET for the diagnosis of spinal cord sarcoidosis will be needed.
